TcLand Licenses Patents to Develop RA Companion Dx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French biomarker firm TcLand Expression today said it has entered a licensing agreement with Inserm Transfert for two patents covering gene expression biomarkers that may be predictive of response to rheumatoid arthritis therapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.